<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Anti-Inflammatory &amp; Anti-Allergy Agents in Medicinal Chemistry</journal-id><journal-title-group><journal-title xml:lang="en">Anti-Inflammatory &amp; Anti-Allergy Agents in Medicinal Chemistry</journal-title><trans-title-group xml:lang="ru"><trans-title>Anti-Inflammatory &amp; Anti-Allergy Agents in Medicinal Chemistry</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1871-5230</issn><issn publication-format="electronic">1875-614X</issn><publisher><publisher-name xml:lang="en">Bentham Science</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">644638</article-id><article-id pub-id-type="doi">10.2174/1871523022666230608094152</article-id><article-categories><subj-group subj-group-type="toc-heading"><subject>Medicine</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Analysis of Tolfenamic Acid using a Simple, Rapid, and Stability-indicating Validated HPLC Method</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kazi</surname><given-names>Sadia</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Sheraz</surname><given-names>Muhammad</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Musharraf</surname><given-names>Syed</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name><surname>Ahmed</surname><given-names>Sofia</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Bano</surname><given-names>Raheela</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><name><surname>Haq</surname><given-names>Faraz</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff5"/></contrib><contrib contrib-type="author"><name><surname>Anwar</surname><given-names>Zubair</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Ali</surname><given-names>Raahim</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff6"/></contrib></contrib-group><aff id="aff1"><institution>Baqai Institute of Pharmaceutical Sciences, Baqai Medical University</institution></aff><aff id="aff2"><institution>Baqai Institute of Pharmaceutical Sciences,, Baqai Medical University</institution></aff><aff id="aff3"><institution>H.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences,, University of Karachi</institution></aff><aff id="aff4"><institution>Dow College of Pharmacy, Dow University of Health Sciences</institution></aff><aff id="aff5"><institution>H.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi</institution></aff><aff id="aff6"><institution>, Baqai Institute of Pharmaceutical Sciences</institution></aff><pub-date date-type="pub" iso-8601-date="2024-01-01" publication-format="electronic"><day>01</day><month>01</month><year>2024</year></pub-date><volume>23</volume><issue>1</issue><fpage>52</fpage><lpage>70</lpage><history><date date-type="received" iso-8601-date="2025-01-07"><day>07</day><month>01</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Bentham Science Publishers</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Bentham Science Publishers</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://transsyst.ru/1871-5230/article/view/644638">https://transsyst.ru/1871-5230/article/view/644638</self-uri><abstract xml:lang="en"><p id="idm46041443642032">Background:Tolfenamic acid (TA) belongs to the fenamates class of non-steroidal anti-inflammatory drugs. Insufficient information is available regarding the availability of a reliable and validated stability-indicating method for the assay of TA.</p><p id="idm46041443646032">Objective:A relatively simple, rapid, accurate, precise, economical, robust, and stability-indicating RP-HPLC method has been developed to determine TA in pure and tablet dosage forms.</p><p id="idm46041443650000">Methods:The method was validated according to the ICH guideline, and parameters like linearity, range, selectivity, accuracy, precision, robustness, specificity, and solution stability were determined. TLC and FTIR spectrometry were used to ascertain the purity of TA. The specificity was determined with known impurities and after performing forced degradation, while the robustness was established by Plackett-Burman's experimental design. The mobile phase used for the analysis was acetonitrile and water (90:10, v/v) at pH 2.5. The detection of the active drug was made at 280 nm using a C18 column (tR = 4.3 min.). The method's ap-plicability was also checked for the yellow polymorphic form of TA.</p><p id="idm46041443655056">Results:The results indicated that the method is highly accurate (99.39-100.80%), precise (&lt;1.5% RSD), robust (&lt;2% RSD), and statistically comparable to the British Pharmacopoeia method with better sensitivity and specificity.</p><p id="idm46041443664432">Conclusion:It was observed that the stress degradation studies do not affect the method's accuracy and specificity. Hence the proposed method can be used to assay TA and its tablet dosage form.</p></abstract><kwd-group xml:lang="en"><kwd>Tolfenamic acid</kwd><kwd>high-performance liquid chromatography</kwd><kwd>validation</kwd><kwd>stability-indicating</kwd><kwd>Plackett-Burman's experimental design</kwd><kwd>polymorphism.</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Rozou, S.; Michaleas, S.; Antoniadou-Vyza, E. Supramolecular interactions between tolfenamic acid and various cyclodextrins: Effects of complexation on physicochemical and spectroscopic data. Pharm. Pharmacol. Commun., 1999, 5(2), 79-84. doi: 10.1211/146080899128734497</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Kovala-Demertzi, D.; Hadjipavlou-Litina, D.; Primikiri, A.; Staninska, M.; Kotoglou, C.; Demertzis, M.A. Anti-inflammatory, antiproliferative, and radical-scavenging activities of tolfenamic acid and its metal complexes. Chem. Biodivers., 2009, 6(6), 948-960. doi: 10.1002/cbdv.200800120 PMID: 19551737</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>British Pharmacopoeia. In: Monograph on tolfenamic acid; Her Majestys Stationary Office: London, UK, 2023.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Sweetman, S. Martindale The Complete Drug Reference; Pharmaceutical Press: London, UK, 2013, pp. 1689-1699.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Pan, L.; Gardner, C.L.; Pagliai, F.A.; Gonzalez, C.F.; Lorca, G.L. Identification of the tolfenamic acid binding pocket in PrbP from Liberibacter asiaticus. Front. Microbiol., 2017, 8, 1591. doi: 10.3389/fmicb.2017.01591 PMID: 28878750</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>British National Formulary (BNF) 84; BMJ Group and Royal Pharmaceutical Society, Pharmaceutical Press: London, UK, 2022, pp. 530-531.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Basha, R.; Ingersoll, S.B.; Sankpal, U.T.; Ahmad, S.; Baker, C.H.; Edwards, J.R.; Holloway, R.W.; Kaja, S.; Abdelrahim, M. Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors. Gynecol. Oncol., 2011, 122(1), 163-170. doi: 10.1016/j.ygyno.2011.03.014 PMID: 21496890</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Liggett, J.L.; Zhang, X.; Eling, T.E.; Baek, S.J. Anti-tumor activity of non-steroidal anti-inflammatory drugs: Cyclooxygenase-independent targets. Cancer Lett., 2014, 346(2), 217-224. doi: 10.1016/j.canlet.2014.01.021 PMID: 24486220</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Feldman, D.; Leahy, E.; Lee, S.H. Chemopreventive properties of tolfenamic acid: A mechanistic review. Curr. Med. Chem., 2018, 25(14), 1598-1608. doi: 10.2174/0929867324666170414155107 PMID: 28413959</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Adwan, L.I.; Basha, R.; Abdelrahim, M.; Subaiea, G.M.; Zawia, N.H. Tolfenamic acid interrupts the de novo synthesis of the β-amyloid precursor protein and lowers amyloid beta via a transcriptional pathway. Curr. Alzheimer Res., 2011, 8(4), 385-392. doi: 10.2174/156720511795745285 PMID: 21557719</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Subaiea, G.M.; Alansi, B.H.; Serra, D.A.; Alwan, M.; Zawia, N.H. The ability of tolfenamic acid to penetrate the brain: A model for testing the brain disposition of candidate Alzheimers drugs using multiple platforms. Curr. Alzheimer Res., 2011, 8(8), 860-867. doi: 10.2174/156720511798192691 PMID: 21605061</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Adwan, L.; Subaiea, G.M.; Zawia, N.H. Tolfenamic acid downregulates BACE1 and protects against lead-induced upregulation of Alzheimers disease related biomarkers. Neuropharmacology, 2014, 79, 596-602. doi: 10.1016/j.neuropharm.2014.01.009 PMID: 24462621</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Moffat, A.C.; Osselton, M.D.; Widdop, B. Clarkes Analysis of Drugs and Poisons, 4th; Pharmaceutical Press: London, UK, 2011, pp. 1646-1647.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Ahmed, S.; Mustaan, N.; Sheraz, M.A.; Nabi, S.A.A.; Ahmad, I. Validation of a UV spectrometric method for the assay of tolfenamic acid in organic solvents. J. Pharm., 2015, 2015, 1-8. doi: 10.1155/2015/216249 PMID: 26783497</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Ahmed, S.; Sheraz, M.A.; Ahmad, I. Tolfenamic Acid.Profiles of Drug Substances, Excipients, and Related Methodology; Brittain, H.G., Ed.; Academic Press: Elsevier: Cambridge, USA, 2018, Vol. 43, pp. 255-319.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Abdelwahab, N.S.; Ali, N.W.; Zaki, M.M.; Abdelkawy, M. Validated chromatographic methods for simultaneous determination of tolfenamic acid and its major impurities. J. Chromatogr. Sci., 2015, 53(4), 484-491. doi: 10.1093/chromsci/bmu071 PMID: 25016532</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Rozou, S.; Antoniadou-Vyza, E. An improved HPLC method overcoming Beers law deviations arising from supramolecular interactions in tolfenamic acid and cyclodextrins complexes. J. Pharm. Biomed. Anal., 1998, 18(4-5), 899-905. doi: 10.1016/S0731-7085(98)00227-1 PMID: 9919995</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Van Eerdenbrugh, B.; Baird, J.A.; Taylor, L.S. Crystallization tendency of active pharmaceutical ingredients following rapid solvent evaporation--classification and comparison with crystallization tendency from undercooled melts. J. Pharm. Sci., 2010, 99(9), 3826-3838. doi: 10.1002/jps.22214 PMID: 20533435</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Gallo, P.; Fabbrocino, S.; Dowling, G.; Salini, M.; Fiori, M.; Perretta, G.; Serpe, L. Confirmatory analysis of non-steroidal anti-inflammatory drugs in bovine milk by high-performance liquid chromatography with fluorescence detection. J. Chromatogr. A, 2010, 1217(17), 2832-2839. doi: 10.1016/j.chroma.2010.02.047 PMID: 20227702</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Gallo, P.; Fabbrocino, S.; Vinci, F.; Fiori, M.; Danese, V.; Nasi, A.; Serpe, L. Multi-residue determination of non-steroidal anti-inflammatory drug residues in animal serum and plasma by HPLC and photo-diode array detection. J. Chromatogr. Sci., 2006, 44(10), 585-590. doi: 10.1093/chromsci/44.10.585 PMID: 17254366</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>de Melo da Silva, L.; Pereira Cavalcante, R.; Fabbro Cunha, R.; Gozzi, F.; Falcao Dantas, R.; de Oliveira, S.C.; Machulek, A. Tolfenamic acid degradation by direct photolysis and the UV-ABC/H2O2 process: Factorial design, kinetics, identification of intermediates, and toxicity evaluation. Sci. Total Environ., 2016, 573, 518-531. doi: 10.1016/j.scitotenv.2016.08.139 PMID: 27575359</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Nielsen-Kudsk, F. HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. Acta Pharmacol. Toxicol., 1980, 47(4), 267-273. doi: 10.1111/j.1600-0773.1980.tb03653.x PMID: 6970498</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Pentikäinen, P.J.; Neuvonen, P.J.; Backman, C. Human pharmacokinetics of tolfenamic acid, a new anti-inflammatory agent. Eur. J. Clin. Pharmacol., 1981, 19(5), 359-365. doi: 10.1007/BF00544587 PMID: 7238564</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Niopas, I.; Georgarakis, M. Pharmacokinetics of tolfenamic acid in pediatric patients after single oral dose. Eur. J. Drug. Meta. Pharmacol., 1995, 20, 293-296.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>McKellar, Q.A.; Lees, P.; Gettinby, G. Pharmacodynamics of tolfenamic acid in dogs. Evaluation of dose response relationships. Eur. J. Pharmacol., 1994, 253(3), 191-200. doi: 10.1016/0014-2999(94)90191-0 PMID: 8200415</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Landoni, M.F.; Cunningham, F.M.; Lees, P. Pharmacokinetics and pharmacodynamics of tolfenamic acid in calves. Res. Vet. Sci., 1996, 61(1), 26-32. doi: 10.1016/S0034-5288(96)90106-X PMID: 8819190</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Lefebvre, H.P.; Laroute, V.; Alvinerie, M.; Schneider, M.; Vinclair, P.; Braun, J.P.; Toutain, P.L. The effect of experimental renal failure on tolfenamic acid disposition in the dog. Biopharm. Drug Dispos., 1997, 18(1), 79-91. doi: 10.1002/(SICI)1099-081X(199701)18:13.0.CO;2-F PMID: 9008271</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Kang, Y.P.; Yu, J.; Huh, Y.; Oh, J.H.; Kwon, C.H.; Lee, S.J.; Ee, J.W.; Kim, G.T.; Lee, J.G.; Lee, J.; Park, J.H.; Kim, Y.S.; Kwon, S.W. Development of high performance liquid chromatography-ultraviolet detection method for screening mebendazole, clorsulon, diaveridine, and tolfenamic acid in animal-based food samples. Drug Test. Anal., 2014, 6(3), 246-256. doi: 10.1002/dta.1467 PMID: 23576386</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Mikami, E.; Goto, T.; Ohno, T.; Matsumoto, H.; Inagaki, K.; Ishihara, H.; Nishida, M. Simultaneous analysis of anthranilic acid derivatives in pharmaceuticals and human urine by high-performance liquid chromatography with isocratic elution. J. Chromatogr., Biomed. Appl., 2000, 744(1), 81-89. doi: 10.1016/S0378-4347(00)00233-4 PMID: 10985569</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Rozou, S.; Michaleas, S.; Antoniadou-Vyza, E. Study of structural features and thermodynamic parameters, determining the chromatographic behaviour of drug-cyclodextrin complexes. J. Chromatogr. A, 2005, 1087(1-2), 86-94. doi: 10.1016/j.chroma.2005.02.039 PMID: 16130701</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Ra, J.S.; Oh, S.Y.; Lee, B.C.; Kim, S.D. The effect of suspended particles coated by humic acid on the toxicity of pharmaceuticals, estrogens, and phenolic compounds. Environ. Int., 2008, 34(2), 184-192. doi: 10.1016/j.envint.2007.08.001 PMID: 17765969</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Guan, J.; Zhang, C.; Wang, Y.; Guo, Y.; Huang, P.; Zhao, L. Simultaneous determination of 12 pharmaceuticals in water samples by ultrasound-assisted dispersive liquid-liquid microextraction coupled with ultra-high performance liquid chromatography with tandem mass spectrometry. Anal. Bioanal. Chem., 2016, 408(28), 8099-8109. doi: 10.1007/s00216-016-9913-1 PMID: 27614980</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Ma, L.; Li, J.; Xu, L. Aqueous chlorination of fenamic acids: Kinetic study, transformation products identification and toxicity prediction. Chemosphere, 2017, 175, 114-122. doi: 10.1016/j.chemosphere.2017.02.045 PMID: 28211324</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Mahghoub, S. Validated RP-HPLC method for quantitative determination of tolfenamic acid and benzyl alcohol in veterinary pharmaceutical preparation. Aus. Chromatogr., 2017, 4, 1046.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Turk, E.; Tekeli, I.O.; Durna Corum, D.; Corum, O.; Altinok Yipel, F.; Ilhan, A.; Emiroglu, S.B.; Uguz, H.; Uney, K. Pharmacokinetics of tolfenamic acid in goats after different administration routes. J. Vet. Pharmacol. Ther., 2021, 44(3), 367-373. doi: 10.1111/jvp.12949 PMID: 33560540</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Turk, E.; Tekeli, I.O.; Corum, O.; Durna Corum, D.; Kirgiz, F.C.; Cetin, G.; Arslan Atessahin, D.; Uney, K. Pharmacokinetics of meloxicam, carprofen, and tolfenamic acid after intramuscular and oral administration in Japanese quails (Coturnix coturnix japonica). J. Vet. Pharmacol. Ther., 2021, 44(3), 388-396. doi: 10.1111/jvp.12972 PMID: 33846990</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Tay, K.S.; Mansor, N.A. The fate of tolfenamic acid in conventional chlorination and UV/chlorination process. Chem. Zvesti, 2022, 76(11), 6869-6877. doi: 10.1007/s11696-022-02378-8</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Blanco-Paniagua, E.; García-Lino, A.M.; García-Mateos, D.; Álvarez, A.I.; Merino, G. Role of the Abcg2 transporter in plasma levels and tissue accumulation of the anti-inflammatory tolfenamic acid in mice. Chem. Biol. Interact., 2021, 345109537 doi: 10.1016/j.cbi.2021.109537 PMID: 34062171</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Gao, L.; Zheng, W.Y.; Yang, W.L.; Zhang, X.R. Drug-drug salt forms of vortioxetine with mefenamic acid and tolfenamic acid. J. Mol. Struct., 2022, 1268, 133725. doi: 10.1016/j.molstruc.2022.133725</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Guideline, H.T. Harmonised Tripartite Guideline. Validation of Analytical Procedures, Text and Methodology Q2(R1 International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use,; Geneva, Switzerland, 2005.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Rasmussen, H.T.; Li, W.; Redlich, D.; Jimidar, M.L. HPLC method development.Handbook of Pharmaceutical Analysis by HPLC; Ahuja, S; Dong, M.W., Ed.; Elsevier Inc.: Amsterdam, The Netherlands, 2005. doi: 10.1016/S0149-6395(05)80050-9</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Andersen, K.V.; Larsen, S.; Alhede, B.; Gelting, N.; Buchardt, O. Characterization of two polymorphic forms of tolfenamic acid, N-(2-methyl-3-chlorophenyl)anthranilic acid: Their crystal structures and relative stabilities. J. Chem. Soc., Perkin Trans. 2, 1989, 2(10), 1443-1447. doi: 10.1039/p29890001443</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Mattei, A.; Li, T. Polymorph formation and nucleation mechanism of tolfenamic acid in solution: An investigation of pre-nucleation solute association. Pharm. Res., 2012, 29(2), 460-470. doi: 10.1007/s11095-011-0574-7 PMID: 21879384</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Sheraz, M.A.; Ahmed, S.; Rehman, I. Effect of pH, polymer concentration and molecular weight on the physical state properties of tolfenamic acid. Pharm. Dev. Technol., 2015, 20(3), 352-360. doi: 10.3109/10837450.2013.871027 PMID: 24417663</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Surov, A.O.; Szterner, P.; Zielenkiewicz, W.; Perlovich, G.L. Thermodynamic and structural study of tolfenamic acid polymorphs. J. Pharm. Biomed. Anal., 2009, 50(5), 831-840. doi: 10.1016/j.jpba.2009.06.045 PMID: 19632801</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Surov, A.O.; Terekhova, I.V.; Bauer-Brandl, A.; Perlovich, G.L. Thermodynamic and structural aspects of some fenamate molecular crystals. Cryst. Growth Des., 2009, 9(7), 3265-3272. doi: 10.1021/cg900002q</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Hartmann, C.; Smeyers-Verbeke, J.; Penninckx, W.; Vander Heyden, Y.; Vankeerberghen, P.; Massart, D.L. Reappraisal of hypothesis testing for method validation: Detection of systematic error by comparing the means of two methods or of two laboratories. Anal. Chem., 1995, 67(24), 4491-4499. doi: 10.1021/ac00120a011</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Rahman, N.; Khan, S. Circular dichroism spectroscopy: An efficient approach for the quantitation of ampicillin in presence of cloxacillin. Spectrochim. Acta A Mol. Biomol. Spectrosc., 2016, 160, 26-33. doi: 10.1016/j.saa.2016.02.009 PMID: 26909703</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Rahman, N.; Sameen, S.; Kashif, M. Spectroscopic study on the interaction of haloperidol and 2, 4-dinitrophenylhydrazine and its application for the quantification in drug formulations. Anal. Chem. Lett., 2016, 6(6), 874-885. doi: 10.1080/22297928.2016.1265898</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Usmani, M.; Ahmed, S.; Ali Sheraz, M.; Ahmad, I. Development and validation of a pre-column derivatization HPLC method for the assay of amikacin sulfate in pure and parenteral dosage forms. Curr. Pharm. Anal., 2019, 15(5), 511-520. doi: 10.2174/1573412914666180314121213</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Gilpin, R.K.; Zhou, W. Infrared studies of the polymorphic states of the fenamates. J. Pharm. Biomed. Anal., 2005, 37(3), 509-515. doi: 10.1016/j.jpba.2004.11.009 PMID: 15740911</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Jabeen, S.; Dines, T.J.; Leharne, S.A.; Chowdhry, B.Z. Raman and IR spectroscopic studies of fenamates - Conformational differences in polymorphs of flufenamic acid, mefenamic acid and tolfenamic acid. Spectrochim. Acta A Mol. Biomol. Spectrosc., 2012, 96, 972-985. doi: 10.1016/j.saa.2012.07.129 PMID: 22954807</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Ahmed, S.; Sheraz, M.A.; Rehman, I.U. Studies on tolfenamic acid-chitosan intermolecular interactions: Effect of pH, polymer concentration and molecular weight. AAPS PharmSciTech, 2013, 14(2), 870-879. doi: 10.1208/s12249-013-9974-9 PMID: 23620261</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Ahmed, S.; Sheraz, M.A.; Yorucu, C.; Rehman, I.U. Quantitative determination of tolfenamic acid and its pharmaceutical formulation using FTIR and UV spectrometry. Cent. Eur. J. Chem., 2013, 11, 1533-1541.</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Andleeb, S.; Ahmed, S.; Sheraz, M.A.; Anwar, Z.; Ahmad, I. Development and validation of a spectrofluorimetric method for the analysis of tolfenamic acid in pure and tablet dosage form. Luminescence, 2020, 35(7), 1017-1027. doi: 10.1002/bio.3810 PMID: 32419348</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Swartz, M.E.; Krull, I.S. Handbook of Analytical Validation, Boca Raton; CRC Press: USA, 2012, pp. 61-100. doi: 10.1201/b12039</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Shrivastava, A.; Saxena, P. Validation of Analytical Methods; Methodology and Statistics, CBS Publishers and Distributors: New Dehli, India, 2014.</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Ahmed, S.; Khan, A.; Sheraz, M.A.; Bano, R.; Ahmad, I. Development and validation of a stability-indicating HPLC method for the assay of carvedilol in pure and tablet dosage forms. Curr. Pharm. Anal., 2018, 14(2), 139-152. doi: 10.2174/1573412913666170525122146</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Singh, R. HPLC method development and validation-an overview. J. Pharm. Edu. Res., 2013, 4, 26-33.</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Lister, A.S. Validation of HPLC methods in pharmaceutical analysis. Handbook of Pharmaceutical Analysis by HPLC; Ahuja, S; Dong, M.W., Ed.; Elsevier Inc.: Amsterdam, The Netherlands, 2005, pp. 191-217. doi: 10.1016/S0149-6395(05)80051-0</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>Thybo, P.; Kristensen, J.; Hovgaard, L. Characterization and physical stability of tolfenamic acid-PVP K30 solid dispersions. Pharm. Dev. Technol., 2007, 12(1), 43-53. doi: 10.1080/10837450601166577 PMID: 17484143</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation>Mattei, A.; Li, T. Interplay between molecular conformation and intermolecular interactions in conformational polymorphism: A molecular perspective from electronic calculations of tolfenamic acid. Int. J. Pharm., 2011, 418(2), 179-186. doi: 10.1016/j.ijpharm.2011.04.062 PMID: 21570454</mixed-citation></ref></ref-list></back></article>
